A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

May 24, 2023

Study Completion Date

August 21, 2023

Conditions

Prevention of Thromboembolic EventsAtrial FibrillationAcute Myocardial InfarctionNon-cardioembolic Ischemic StrokeHepatic Impairment

Interventions

DRUG

Asundexian (BAY2433334)

Study intervention BAY2433334 will be administered as tablet taken orally.

Trial Locations (1)

CRS-Kiel, Kiel